Recovery of mitophagic function via NAD+ supplementation, PINK1 overexpression, urolithin A, or actinonin recovers some aspects of AD pathology, such as reducing levels of insoluble amyloid beta, reducing levels of hyperphosphorylated tau, and preventing cognitive impairment (Du et al., 2017; Fang et al., 2019). The gene discussed is MAPT; the disease is Alzheimer disease.